Expression of an antigenic adenovirus in a group B coxsackievirus

Journal of Virology

Volumn 74, Issue 10, 2000, Pages 4570-4578

  Höfling, Katja ^a   Tracy, Steven ^a   Chapman, Nora ^a   Kim, Kyung Soo ^a   Leser, J Smith ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPSID PROTEIN; EPITOPE; NEUTRALIZING ANTIBODY; VIRUS PROTEIN;

ADENOVIRUS; ANIMAL CELL; ANTIBODY TITER; ANTIGEN EXPRESSION; ARTICLE; COXSACKIE VIRUS B; DNA FLANKING REGION; GENE INDUCTION; HUMAN; HUMAN CELL; IMMUNE RESPONSE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VIRUS GENOME; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; BASE SEQUENCE; BLOTTING, WESTERN; CAPSID; CAPSID PROTEINS; CELLS, CULTURED; ENTEROVIRUS B, HUMAN; EPITOPES; GENETIC VECTORS; GENOME, VIRAL; HUMANS; MALE; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; RABBITS; RECOMBINANT FUSION PROTEINS; VIRUS REPLICATION;

EID: 0342264636     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.10.4570-4578.2000     Document Type: Article

References (68)

1. Abraham, R., P. Minor, G. Dunn, J. F. Modlin, and P. L. Ogra. 1993. Shedding of virulent poliovirus revertants during immunization with oral poliovirus vaccine after prior immunization with inactivated polio vaccine. J. Infect. Dis. 168:1105-1109.
2. Anderson, M., D. Porter, P. Fultz, and C. Morrow. 1996. Poliovirus replicons that express the gag or the envelope surface protein of simian immunodeficiency virus SIV(smm) PBj14. Virology 219:140-149.
3. Arnold, G. F., D. A. Resnick, A. D. Smith, S. C. Geisler, A. K. Holmes, and E. Arnold. 1996. Chimeric rhinoviruses as tools for vaccine development and characterization of protein epitopes. Intervirology 39:72-78.
4. Arola, A., H. Kalimo, O. Ruuskanen, and T. Hyypia. 1995. Experimental myocarditis induced by two different coxsackievirus B3 variants: aspects of pathogenesis and comparison of diagnostic methods. J. Med. Virol. 47:251-259.
5. Baboonian, C., M. J. Davies, J. Booth, and W. McKenna. 1997. Coxsackie B viruses and heart disease. Curr. Top. Microbiol. Immunol. 223:31-52.
6. Basak, S., S. McPherson, S. Kang, J. F. Collawn, and C. D. Morrow. 1998. Construction and characterization of encapsidated poliovirus replicons that express biologically active murine interleukin 2. J. Interferon Cytokine Res. 18:305-313.
7. Beck, M., and S. Tracy. 1989. Murine cell-mediated immune response recognizes an enterovirus group-specific antigen(s). J. Virol. 63:4148-4156.
8. Beck, M., and S. Tracy. 1990. Evidence for a group-specific enteroviral antigen(s) recognized by human T cells. J. Clin. Microbiol. 28:1822-1827.
9. Bergelson, J. M., A. Krithivas, L. Celi, G. Droguett, M. S. Horwitz, T. Wickham, R. L. Crowell, and R. W. Finberg. 1998. The murine CAR homolog is a receptor for coxsackie B viruses and adenoviruses. J. Virol. 72:415-419.
10. Bramson, J. L., M. Hitt, J. Gauldie, and F. L. Graham. 1997. Pre-existing immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4:1069-1076.
11. Burch, G. E., and T. D. Giles. 1972. The role of viruses in the production of heart disease. Am. J. Cardiol. 29:231-240.
12. Carson, S., N. Chapman, and S. Tracy. 1997. Purification of the putative coxsackievirus B receptor from HeLa cells. Biochem. Biophys. Res. Commun. 233:325-328.
13. Chan, S.-Y., K. Li, J. R. Piccotti, M. C. Louie, T. A. Judge, L. A. Turka, E. J. Eichwald, and D. K. Bishop. 1999. Tissue-specific consequences of the anti-adenoviral immune response: implication for cardiac transplants. Nat. Med. 5:1143-1149.
14. Chapman, N., A. Ragland, J. S. Leser, K. Höfling, S. Willian, B. L. Semler, and S. Tracy. 2000. A group B coxsackievirus/poliovirus 5' nontranslated region chimera can act as an attenuated vaccine strain in mice. J. Virol. 74:4047-4056.
15. Chapman, N., J. Romero, M. Pallansch, and S. Tracy. 1997. Sites other than nucleotide 234 determine cardiovirulence in natural isolates of coxsackievirus B3. J. Med. Virol. 52:258-261.
16. Chapman, N., Z. Tu, S. Tracy, and C. Gauntt. 1994. An infectious cDNA copy of the genome of a non-cardiovirulent coxsackievirus B3 strain: Its complete sequence analysis and comparison to the genomes of cardiovirulent coxsackieviruses. Arch. Virol. 135:115-130.
17. Choi, S. W., R. Pal-Ghosh, and C. D. Morrow. 1991. Expression of human immunodeficiency virus type 1 (HIV-1) gag, pol, and env proteins from chimeric HIV-1-poliovirus minireplicons. J. Virol. 65:2875-2873.
18. Crabbe, M., D. Evans, and J. Almond. 1990. Modelling of poliovirus. HIV1 antigen chimaeras. FEBS Lett. 271:194-198.
19. Crotty, S., B. L. Lohman, F. S. Lu, S. Tang, C. J. Miller, and R. Andino. 1999. Mucosal immunization of cynomolgus macaques with two scrotypes of live poliovirus vectors expressing simian immunodeficiency virus antigens: Stimulation of humoral, mucosal and cellular immunity. J. Virol. 73:9485-9495.
20. Dalldorf, G. 1955. The coxsackie viruses. Annu. Rev. Microbiol. 9:277-296.
21. Disney, M. E., E. M. Howard, and B. S. B. Wood. 1953. Myocarditis in children. Br. Med. J. 1:1351-1354.
22. Dove, A. and V. Racaniello. 1997. The polio eradication effort: should vaccine eradication be next? Science 277:779-780.
23. Dowdle, W. R., and M. E. Birmingham. 1997. The biologic principles of poliovirus eradication. J. Infect. Dis. 175(Suppl. 1):S286-S292.
24. Dowdle, W. R., D. A. Featherstone, M. F. Birmingham, H. F. Hull, and R. Aylward. 1999. Poliomyelitis eradication. Virus Res. 62:185-192.
25. Evans, D., J. McKeating, J. M. Meredith, K. L. Burke, K. Katrack, A. John, M. Ferguson, P. D. Minor, R. Weiss, and J. W. Almond. 1989. An engineered poliovirus chimaera elicits broadly reactive HIV1 neutralizing antibodies. Nature 339:385-388.
26. Francki, R., C. Fauquet, D. knudson, and F. Brown. 1991. Classification and nomenclature of viruses. Springer-Verlag, Vienna, Austria.
27. Gauntt, C., A. Higdon, D. Bowers, E. Maull, J. Wood, and R. Crawley. 1993. What lessons can be learned from animal model studies in viral heart disease? Scand. J. Infect. Dis. Suppl. 88:49-65.
28. Gauntt, C., M. Trousdale, D. LaBadie, R. E. Paque, and T. Nealon. 1979. Properties of coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J. Med. Virol. 3:207-220.
29. Girard, M., A. Martin, and S. van der Werf. 1993. Potential use of poliovirus as a vector. Biologicals 21:371-377.
30. Gomez, R., E. Lascano, and M. Berria. 1991. Murine acinar pancreatitis preceding necrotizing myocarditis after coxsackievirus B3 inoculation. J. Med. Virol. 35:71-75.
31. Graff, J., O. C. Richards, K. M. Swidereck, M. T. Davis, F. Rusnack, S. A. Harmon, X. Jia, D. F. Summers, and E. Ehrenfeld. 1999. Hepatitis A virus capsid protein VP1 has a heterogeneous C terminus. J. Virol. 73:6015-6023.
32. Guida, J. D., G. Fejer, L.-A. Pirofski, C. F. Brosnan, and M. S. Horwitz. 1995. Mouse adenovirus type 1 causes a fatal hemorrhagic encephalmyelitis in adult C57BL/6 but not BALB/c mice. J. Virol. 69:7674-7681.
33. Huber, S. A. 1997. Autoimmunity in myocarditis: relevance of animal models. Clin. Immunol. Immunopathol. 83:93-102.
34. Huber, S. A. 1988. The role of immune mechanisms in pathogenesis, p. 103-116, In M. Bendinelli and H. Friedman (ed.), Coxsackieviruses: a general update. Plenum Press, New York, N.Y.
35. Kibrick, S., and K. Benirschke. 1958. Severe generalized disease (encephalohepatomyocarditis) occurring in the newbord period and due to infection with coxsackie virus, group B. Pediatrics 22:857-874.
36. Laemmli, U. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
37. Lee, C., E. Maull, N. Chapman, S. Tracy, G. Wood, and C. Gauntt. 1997. Generation of an infectious cDNA of a highly cardiovirulent coxsackievirus B3(CVB3m) and comparison to other infectious CVB3 cDNAs. Virus Res. 50:225-235.
38. Mandl, S., L. Sigal, K. Rock, and R. Andino. 1998. Poliovirus vaccine vectors elicit antigenic specific cytotoxic T cells and protect mice against lethal challenge with malignant melanoma cells expressing a model antigen. Proc. Natl. Acad. Sci. USA 95:8216-8221.
39. Martin, A., D. Benichou, S.-F. Chao, L. M. Cohen, and S. M. Lemon. 1999. Maturation of the hepatitis A virus capsid protein VP1 is not dependent on processing by the 3Cpro proteinase. J. Virol. 73:6220-6227.
40. Martin, A. B., S. Webber, F. J. Fricker, R. Jaffe, G. Demmler, D. Kearney, Y. H. Zhang, J. Bodurtha, B. Gelb, J. Ni, J. Bricker, and J. Towbin. 1994. Acute myocarditis. Rapid diagnosis by PCR in children. Circulation 90:330-339.
41. Martino, T. A., P. Liu, M. Petric, and M. J. Sole. 1995. Enteroviral myocarditis and dilated cardiomyopathy: a review of clinical and experimental studies, p. 291-352. In H. A. Rotabart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
42. Mattion, N. M., P. A. Reilly, S. J. DiMichele, J. Crowley, and C. Weeks-Levy. 1994. Attenuated poliovirus strain as a live vector: expression of regions of rotavirus outer capsid protein VP7 by using recombinant Sabin 3 viruses. J. Virol. 68:3925-3933.
43. Modlin, J. 1995. Poliomyelitis and poliovirus immunization, p. 195-220. In H. A. Rotbart (ed.), Human enterovirus infections. ASM Press, Washington, D.C.
44. Molnar-Kimber, K. L., D. H. Sterman, M. Chang, E. H. Kang, M. ElBash, M. Lanuti, A Elshami, K. Gelfand, J. M. Wilson, L. R. Kaiser, and S. M. Albelda. 1998. Impact of preexisting and induced humoral and cellular immune responses in an adenovirus-based gene therapy phase I clinical trial for localized mesothelioma. Hum. Gene Ther. 9:2121-2133.
45. Morrow, C., M. Novak, C. Ansardi, D. C. Porter, and Z. Moldoveanu. 1999. Recombinant viruses as vectors for mucosal immunity. Curr. Top. Microbiol. Immunol. 236:255-273.
46. Mucklebaur, J. K., M. Kremer, I. Minor, G. Diana, F. J. Dutko, J. Groarke, D. C. Pevear, and M. G. Rossmann. 1995. The structure of coxsackievirus B3 at 3.5 angstrom resolution. Structure 15:653-667.
47. Mucklebaur, J. K., and M. G. Rossmann. 1997. The structure of coxsackievirus B3. Curr. Top. Microbiol. Immunol. 223:191-208.
48. Mueller, S., and E. Wimmer. 1998. Expression of foreign proteins by poliovirus polyprotein fusion: analysis of genetic stability reveals rapid deletions and formation of cardioviruslike open reading frames. J. Virol. 72:20-31.
49. Novak, J. E., and K. Kirkegaard. 1994. Coupling between genome translation and replication in an RNA virus. Genes Dev. 8:1726-1737.
50. Novak, M. J., L. E. Smythies, S. A. McPherson, D. Smith, and C. D. Morrow. 1999. Poliovirus replicons encoding the B subunit of Helicobacter pylori urease elicit a Th1 associated immune response. Vaccine 17:2384-2391.
51. Nugent, C. I., K. L. Johnson, P. Sarnow, and K. Kirkegaard. 1999. Functional coupling between replication and packaging of poliovirus replicon RNA. Virology 73:427-435.
52. Pallansch, M. 1997. Coxsackievirus B epidemiology and public health concerns. Curr. Top. Microbiol. Immunol. 223:13-30.
53. Pauschinger, M., N. E. Bowles, F. J. Fuentes-Garcia, V. Pham, U. Kuhl, P. L. Schwimmbeck, H. Schultheiss, and J. Towbin. 1999. Detection of adenoviral genome in the myocardium of adult patients with idiopathic left ventricular dysfunction. Circulation 99:1348-1354.
54. Porter, D., C. Ansardi, W. S. Choi, and C. Morrow. 1993. Encapsidation of genetically engineered poliovirus minireplicons which express human immunodeficiency virus type 1 Gag and Pol proteins upon infection. J. Virol. 67:3712-3719.
55. Probst, C., M. Jecht, and V. Gauss-Muller. 1999. Intrinsic signals for the assembly of hepatitis A virus particles. Role of structural proteins VP4 and 2A. J. Biol. Chem. 274:4527-4531.
56. Rose, N. R., D. A. Neumann, and A. Herskowitz. 1988. Genetics of susceptibility to viral myocarditis in mice. Pathol. Immunopathol. Res 7:266-278.
57. Rose, N. R., D. A. Neumann, and A. Herskowitz. 1992. Coxsackievirus myocarditis. Adv. Intern. Med. 37:411-429.
58. Sabin, A. B., and L. R. Boulger. 1973. History of Sabin attenuated poliovirus oral live vaccine strains. J. Biol. Stand. 1:115-118.
59. Tang, S., R. van Rij, D. Silvera, and R. Andino. 1997. Toward a poliovirusbased simian immunodeficiency virus vaccine: correlation between genetic stability and immunogenicity. J. Virol. 71:7841-7850.
60. Tomko, R. P., R. Xu, and L. Philipson. 1997. HCAR and MCAR: the human and mouse cellular receptors for subgroupC adenoviruses and group B coxsackieviruses. Proc. Natl. Acad. Sci. USA 94:3352-3356.
61. Toogood, C., J. Crompton, and R. Hay. 1992. Antipeptide antisera define neutralizing epitopes on the adenovirus hexon. J. Gen. Virol. 73:1429-1435.
62. Tracy, S., N. Chapman, B. McManus, M. Pallansch, M. Beck, and J. Carstens. 1990. A molecular and serologic evaluation of enteroviral involvement in human myocarditis. J. Mol. Cell. Cardiol. 22:403-414.
63. Tracy, S., N. Chapman, and Z. Tu. 1992. Coxsackievirus B3 from an infectious cDNA copy of the genome is cardiovirulent in mice. Arch. Virol. 122:399-409.
64. Tracy, S., K. Hofling, S. Pirruccello, P. H. Lane, S. M. Reyna, and C. Gauntt. Group B coxsackievirus myocarditis and pancreatitis in mice: connection between viral virulence phenotypes. J. Med. Virol., in press.
65. Tu, Z., N. Chapman, G. Hufnagel, S. Tracy, J. R. Romero, W. H. Barry, K. Currey, and B. Shapiro. 1995. The cardiovirulent phenotype of coxsackievirus B3 is determined at a single site in the genomic 5' nontranslated region. J. Virol. 69:4607-1618.
66. Verlinde, J., H. Van Tongeren, and A. Kret. 1956. Myocarditis in newborns due to group B coxsackievirus: virus studies. Acta Pediatr. 187:113-118.
67. Woodruff, J. F. 1980. Viral myocarditis: a review. Am. J. Pathol. 101:425-484.
68. Yim, T., S. Tang, and R. Andino. 1996. Poliovirus recombinants expressing hepatitis B virus antigens elicited a humoral immune response in susceptible mice. Virology 218:61-70.